Optimizing Therapy for Patients with Acute and Chronic Graft-Versus-Host Disease (GvHD)

Moderator Michael Bishop, MD introduces expert panelists and leads an overview of Graft-Versus-Host Disease, covering the differences between chronic and acute conditions, how GvHD is typically diagnosed, and GvHD risk assessment.

Panelists Hannah Choe, MD, and Bart L Scott, MD share insights concerning prophylaxis in Graft-Versus-Host Disease, including key study data and current standards of care as well as discuss the potential role of biomarkers in GvHD.

Subject-matter experts delve into the diagnosis, risk assessment, and treatment selection process for acute GvHD, emphasizing differentiation of refractory disease.

Treatment options for steroid refractory acute GvHD, including ruxolitinib efficacy and NCCN guideline adherence, take center stage in the discussion.

Supportive care measures for acute GvHD are explored, highlighting strategies to manage symptoms and improve patient well-being.

Experienced clinicians discuss the future of acute GvHD treatment, focusing on gaps in patient care and potential therapy options.

Insights on treatment strategies and goals for initial chronic GvHD management, including treatment selection rationale and dosing.

Exploring FDA-approved treatment options for patients with chronic GvHD, with a focus on trial data and adverse effects.

Clinical pearls for community oncologists regarding treatment selection and sequencing in chronic GvHD patients.

Addressing patient monitoring in chronic GvHD, including therapy adjustment indicators and frequency.

Expert panelists share final thoughts concerning the future of chronic GvHD treatment, highlighting unmet needs, ongoing trials, and promising therapies.

Robert M. Rifkin, MD, FACP, offers advice to colleagues about belantamab mafodotin as a treatment option for patients with relapsed/refractory multiple myeloma.

Lead presenter Passi Jaane, MD, PhD presents key data on the FLAURA2 trial presented at ESMO 2025. 

Surbhi Sidana, MD, discusses the FDA approval of BVd for relapsed or refractory multiple myeloma.